Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease metabolic syndrome x
Symptom C0311277|central obesity
Sentences 18
PubMedID- 24117923 Some of the diagnostic components of metabolic syndrome, including central obesity, fasting glucose, triglycerides and blood pressure in phase i and central obesity, triglycerides and hdl cholesterol in phase ii, were significantly improved as a cohort (table 1).
PubMedID- 20180954 It is however pertinent to note that although the specific role of central obesity in patients with the metabolic syndrome remains unexplained, active brown adipocytes which accumulate in central locations have been found to be metabolically active.
PubMedID- 20981493 Lower testosterone levels were associated with central obesity- a strong component of a metabolic syndrome, and unsubstituted testosterone deficiency might be an important cardiovascular risk factor in patients with hypopituitarism.
PubMedID- 24111227 Ultrasonography-based visceral fat estimation is a promising method to assess central obesity, which is associated with metabolic syndrome.
PubMedID- 24082792 Hypertension has been described as one of the most important factors for the development of metabolic syndrome,27,29–31 together with central obesity.27,30,31 however, the criteria for central obesity also differed among the various studies, some of which measured it according to waist circumference while others used the body mass index.
PubMedID- 23435016 In mice, a two to three-fold elevation of 11β-hsd1 selectively in adipose tissue phenocopies the metabolic syndrome, with central obesity, insulin resistance, dyslipidaemia and hypertension whereas similar transgenic expression of 11β-hsd2 in adipocytes (it is not normally expressed in adipocytes), presumably lowering intra-adipose glucocorticoid action, causes insulin sensitisation in high fat fed mice .
PubMedID- 22150400 This association was mainly driven by the central obesity component of the metabolic syndrome.
PubMedID- 25888859 Nash is considered the hepatic manifestation of the metabolic syndrome and is associated with central obesity, insulin resistance, diabetes, essential hypertension, and dyslipidemia .
PubMedID- 25506401 Background: adipocyte-derived factors and regulators likely contribute to the metabolic syndrome (mets) in patients with central obesity.
PubMedID- 20619835 Background: the metabolic syndrome (mets) is associated with central obesity and leads to increased morbidity and mortality due to cardiovascular disease (cvd).
PubMedID- 22829741 The commoncomponents of metabolic syndrome included central obesityand dyslipidemia in our study.
PubMedID- 20615436 Leptin, adiponectin and ghrelin were more closely related to insulin resistance and central obesity as core components of the metabolic syndrome.
PubMedID- 22537054 The numbers of positive components in metabolic syndrome between subjects with central obesity and without central obesity.
PubMedID- 20944981 central obesity is associated with osas and metabolic syndrome, and there is evidence that obstructive sleep apnea is an independent risk factor for obesity, glucose intolerance and insulin resistance.
PubMedID- 26558034 The latter must be viewed as a novel renal manifestation of insulin resistance in the context of metabolic syndrome with central obesity as its primary key feature.
PubMedID- 25833179 Lipodystrophy diagnosis can be challenging, and it has been suggested that partial forms can be easily misdiagnosed as common central obesity with associated metabolic syndrome.
PubMedID- 25610182 Objective: metabolic syndrome (ms) presents with central obesity, impaired glucose metabolism, dyslipidemia and hypertension.
PubMedID- 25885657 Participants satisfying the full criteria will be classified as having metabolic syndrome; whereas those with central obesity (waist circumference >94 cm men or >80 cm women europids, sub-saharan africans, eastern mediterranean, middle east; >90 cm men or >80 cm women south asians, chinese, japanese) plus any one of: raised triglyceride level (>1.7 mm, or treatment for this); reduced hdl-cholesterol (<1.03 mm in males and <1.29 mm in females, or treatment for this); will be classified as being at risk of metabolic syndrome.

Page: 1